Budget Impact Analysis of Dapagliflozin in Treating Patients With Heart Failure With Reduced Ejection Fraction From the Perspective of Malaysian Public Healthcare System.
從馬來西亞公共醫療系統的角度分析 Dapagliflozin 在治療射血分數降低的心力衰竭患者中的預算影響。
Clin Ther 2024-09-11
Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review.
dapagliflozin 在管理收縮功能降低型心衰竭(HFrEF)中的成本效益分析:一個系統性回顧。
Cost Eff Resour Alloc 2022-12-13
Cost Effectiveness of Adding Dapagliflozin to Standard Care in Heart Failure Patients with Reduced Ejection Fraction: A Systematic Review.
將此醫學文章的標題翻譯為繁體中文:「將達帕格酮添加至標準治療對心衰患者降低射血分數的成本效益性:系統性回顧」。
Am J Cardiovasc Drugs 2023-03-14
Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction.
達帕格列酮和恩帕格列酮治療降低射出分數心衰的成本效益性。
Int J Cardiol 2023-06-27
Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia.
將此醫學文章的標題翻譯為繁體中文(zh-TW):「將 empagliflozin 加入標準治療方案對馬來西亞心臟衰竭患者的成本效益分析」。
Front Pharmacol 2023-07-01
Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis.
將達帕格醇在慢性腎臟病中降低醫療資源利用和成本的效力轉化為醫療保健成本抵銷分析。
J Med Econ 2024-01-13
Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
非糖尿病心衰竭患者添加達帕格魯洛治療的成本效益性。
J Med Econ 2024-03-12
Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials.
Dapagliflozin對心臟衰竭在射出分數範圍內的成本效益:基於DELIVER和DAPA-HF試驗的合併個別參與者數據的經濟評估。
J Am Heart Assoc 2024-03-19
Beyond Clinical Trials - The cost-saving associated with dapagliflozin use in portuguese hospital clinical practice.
超越臨床試驗 - dapagliflozin 在葡萄牙醫院臨床實踐中的成本節省。
Rev Port Cardiol 2024-07-27
Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction.
empagliflozin 在治療馬來西亞慢性心衰竭及保留或輕度降低射血分數患者中的成本效益分析。
PLoS One 2024-08-23